Scientists have uncovered a critical piece of the puzzle in autoimmune diseases: a protein that helps release immune response ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

In a new study, researchers explored experiences, perceptions, and health effects of a newly developed healthy lifestyle ...

A minimum of 3 years of sustained clinical remission may protect against an increase in disease activity and the development ...

The FDA has agreed to review an application from Roche that seeks approval in the U.S. of obinutuzumab as a treatment for ...

Rage and autoimmune disease: is there a link between suppressed anger and the women’s health crisis? - In the midst of a ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with ...

In December 2024, the National Comprehensive Cancer Network® (NCCN) added AUCATZYL (obecabtagene autoleucel) to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of ...

The oral mucosa represents a fascinating scenario in the setting of medical research for its peculiar immune mileu. Not only the oral cavity hosts specific immune cells interacting with the local ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...